Sustainability, Rare Disease Trials, Digital Innovation, Global Workforce, Stock Performance, Patient Access, and Regulatory Challenges** in Chinese is:**艾伯维:可持续性、罕见病临床试验、数字创新、全球员工
Emerging Markets, IP Management, Partnerships, Humira Patent, and M&A Growth** to Chinese is:**艾克维战略:新兴市场、知识产权管理、合作伙伴关系、Humira专利及并购增长**【abbv abbvie inc】
AbbVie’s Leadership in Drug Innovation: R&D Strategies, Biosimilars, Immunology, Oncology, and Pipeline Comparison with Top Pharma Companies【abbv abbvie inc】